Fusac Topical (fusidic acid, topical): Uses, Dosage & Side Effects

What it's for (Indications)

Topical fusidic acid, such as Dermy, is indicated for the treatment of primary and secondary bacterial skin infections caused by susceptible strains of *Staphylococcus aureus*, *Streptococci*, and *Corynebacterium minutissimum*.
Primary skin infections treatable with fusidic acid include impetigo, folliculitis, furunculosis, erythrasma, paronychia, and sycosis barbae.
Secondary infections where it is effectively utilized encompass infected dermatitis (e.
g.
, atopic dermatitis, seborrheic dermatitis, contact dermatitis), infected cuts, abrasions, and minor burns.
Its utility is specifically targeted towards infections confirmed or strongly suspected to be sensitive to fusidic acid, thereby emphasizing its role in combating superficial skin pathogens with known susceptibility profiles.
The decision to initiate therapy should consider local antimicrobial resistance patterns and official guidance on appropriate antibacterial use to ensure efficacy and minimize the development of resistance.

Dosage Information

Type	Guideline
Standard	For topical fusidic acid, the recommended dosage involves applying a thin film to the affected skin area two to three times daily. The treated area may or may not be covered with a sterile dressing, depending on clinical necessity and patient comfort. The typical duration of treatment is generally 7 to 10 days, although this may vary based on the severity and nature of the infection, as well as the clinical response observed. It is crucial to emphasize that treatment should not usually exceed 14 days without a re-evaluation by a healthcare professional to assess the ongoing need for therapy and to mitigate the risks associated with prolonged antimicrobial use, such as the development of resistance or superinfection. Patients should be instructed on proper application techniques, including washing hands before and after application, to ensure optimal hygiene and prevent the spread of infection.

Type

Guideline

Standard

For topical fusidic acid, the recommended dosage involves applying a thin film to the affected skin area two to three times daily. The treated area may or may not be covered with a sterile dressing, depending on clinical necessity and patient comfort. The typical duration of treatment is generally 7 to 10 days, although this may vary based on the severity and nature of the infection, as well as the clinical response observed. It is crucial to emphasize that treatment should not usually exceed 14 days without a re-evaluation by a healthcare professional to assess the ongoing need for therapy and to mitigate the risks associated with prolonged antimicrobial use, such as the development of resistance or superinfection. Patients should be instructed on proper application techniques, including washing hands before and after application, to ensure optimal hygiene and prevent the spread of infection.

Safety & Warnings

Common Side Effects

Topical fusidic acid is generally well-tolerated, but like all medications, it can cause side effects.
The most commonly reported adverse reactions are local application site reactions, which may include irritation, burning, stinging, itching, dryness, erythema (redness), and rash.
These reactions are typically mild and transient.
Less common, but potentially more serious, side effects include various hypersensitivity reactions such as allergic contact dermatitis, urticaria (hives), and angioedema, which may manifest as swelling of the face, lips, tongue, or throat, and can be associated with breathing difficulties.
Other rare but significant adverse effects include periorbital edema if applied near the eyes, and in some instances, exacerbation of eczema.
Prolonged or extensive use may also lead to the overgrowth of non-susceptible organisms, including fungi (e.
g.
, *Candida*) or resistant bacteria, resulting in a superinfection.
Patients should be advised to discontinue use and consult a healthcare professional if they experience severe or persistent local reactions or any signs of a systemic allergic reaction.

Serious Warnings

Black Box Warning: ### SERIOUS WARNINGS: Risk of Antimicrobial Resistance and Superinfection Topical fusidic acid, while effective for susceptible bacterial skin infections, carries significant risks associated with its misuse or overuse that warrant serious consideration. There is a substantial risk of developing antimicrobial resistance, particularly in *Staphylococcus aureus*, including Methicillin-Resistant *Staphylococcus aureus* (MRSA), if the product is used inappropriately, for prolonged periods, or for infections caused by non-susceptible organisms. The emergence of resistance can severely limit future treatment options for serious infections. Therefore, it is critically important to restrict fusidic acid use to confirmed or strongly suspected fusidic acid-susceptible bacterial infections and for the shortest duration necessary to achieve clinical cure, typically not exceeding 14 days without re-evaluation. Additionally, prolonged treatment or widespread application may lead to the overgrowth of non-susceptible organisms, including fungi (e.g., *Candida*) or other resistant bacteria, resulting in secondary infections or superinfections. These superinfections may require alternative antimicrobial therapy and can complicate patient management. Patients must be carefully monitored for signs of new infection or worsening of existing conditions during and after treatment. Any signs of severe local reactions, widespread rash, or systemic hypersensitivity reactions, such as angioedema, necessitate immediate discontinuation of the drug and prompt medical consultation. Healthcare professionals should educate patients on the judicious use of antibiotics and the importance of adhering to prescribed treatment durations.
Topical fusidic acid preparations are intended for external use only and should not be used for ophthalmic purposes.
Careful consideration must be given to avoid contact with the eyes, as it may cause irritation.
Prolonged or widespread use of fusidic acid should be avoided due to the potential risk of developing bacterial resistance and the possibility of superinfection with non-susceptible organisms, particularly fungi.
If treatment duration exceeds the recommended period without significant improvement, or if the condition worsens, re-evaluation by a physician is imperative to confirm the diagnosis and adjust the therapeutic strategy.
Hypersensitivity reactions, including severe presentations like angioedema, have been reported; patients should be advised to seek immediate medical attention if symptoms of a severe allergic reaction occur.
Caution is advised when prescribing to pregnant or lactating women, and to pediatric populations, as systemic absorption, while minimal, should be considered, and the benefit-risk profile carefully assessed by a healthcare provider.
Fusidic acid is not indicated for deep-seated infections or those with systemic manifestations.

How it Works (Mechanism of Action)

Fusidic acid exerts its antibacterial action primarily by inhibiting bacterial protein synthesis. It achieves this by interfering with the translocation of elongation factor G (EF-G) from the ribosome, a crucial step in the process of protein synthesis. Specifically, fusidic acid binds to EF-G, forming a stable complex that prevents the release of EF-G from the ribosome after GTP hydrolysis. This inhibition effectively blocks the subsequent movement of the ribosome along the messenger RNA, thereby preventing the elongation of the polypeptide chain and halting the synthesis of essential bacterial proteins. This mechanism renders fusidic acid predominantly bacteriostatic at lower concentrations, meaning it inhibits bacterial growth, but can be bactericidal at higher concentrations against highly susceptible organisms. Its unique mechanism of action contributes to its effectiveness against Gram-positive bacteria, particularly *Staphylococcus aureus*, which are often implicated in skin infections, while minimizing cross-resistance with other commonly used antibiotics that target different biochemical pathways.